medicina58巻10号

2021年09月発行

特集 腎疾患—エキスパートへの質問で学ぶ診療のキホンと最新情報 膠原病

痛風の尿酸降下療法：薬剤選択と血清尿酸値の治療目標値について教えてください

著者： 谷口敦夫¹

所属機関： ¹結核予防会複十字病院膠原病リウマチ科

ページ範囲：P.1580 - P.1584

Point
◎病因について，「痛風は高尿酸血症の合併症の一つである」あるいは「痛風は尿酸塩結晶による関節炎を繰り返す疾患である」という考え方では，痛風における尿酸降下療法の意義は理解しにくい．
◎「痛風は関節内に尿酸塩結晶が持続的に沈着する疾患である」という考え方に基づき，痛風の尿酸降下療法を進めるのが適切である．
◎薬物による尿酸降下療法では，適応症例の選択，治療目標値，薬剤の選択，治療開始時期，治療期間を考慮する必要がある．

参考文献

1）Dalbeth N, et al：Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout；A dual energy CT study. Ann Rheum Dis 74：908-911, 2015

2）Dalbeth N, et al：Hyperuricaemia and gout；Time for a new staging system? Ann Rheum Dis 73：1598-1600, 2014

3）Bardin T, et al：1. Gout. Bijlsma JWJ（ed）：Textbook on Rheumatic Diseases 2nd edition, pp 344-358, BMJ, London, 2015

4）Richette P, et al：2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76：29-42, 2017

5）FitzGerald JD, et al：2020 American college of rheumatology guideline for the management of gout. Arthritis Care Res（Hoboken） 72：744-760, 2020

6）Pascart T, et al：2020 recommendations from the French Society of Rheumatology for the management of gout；Urate-lowering therapy. Joint Bone Spine 87：395-404, 2020

7）Zhang W, et al：EULAR evidence based recommendations for gout. Part Ⅱ：Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics（ESCISIT）. Ann Rheum Dis 65：1312-1324, 2006

8）Kuo C-F, et al：Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. JAMA 312：2684-2686, 2014

9）Dalbeth N, et al：Effects of Febuxostat in early gout；A randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 69：2386-2395, 2017

10）Doherty M, et al：Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout；A randomised controlled trial. Lancet 392：1403-1412, 2018

11）Dalbeth N, et al：Effects of allopurinol dose escalation on bone erosion and urate volume in gout；A dual-energy computed tomography imaging study within a randomized, controlled trial. Arthritis Rheumatol 71：1739-1746, 2019

12）Perez-Ruiz F, et al：Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 47：356-360, 2002

13）Richette P, et al：SUA levels should not be maintained ＜3 mg/dL for several years. Response to “EULAR gout treatment guidelines by Richette et al：uric acid and neurocognition by Singh et al”. Ann Rheum Dis 77：e21, 2018

14）Singh JA, et al：EULAR gout treatment guidelines by Richette et al.：Uric acid and neurocognition. Ann Rheum Dis 77：e20, 2018

15）Taylor TH, et al：Initiation of allopurinol at first medical contact for acute attacks of gout；A randomized clinical trial. Am J Med 125：1126-1134. e7, 2012

16）White WB, et al：Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378：1200-1210, 2018

17）FDA adds Boxed Warning for increased risk of death with gout medicine Uloric（febuxostat）　https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning-increased-risk-death-gout-medicine-uloric-febuxostat（2021年7月閲覧）

18）Mackenzie IS, et al：Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout（FAST）；A multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet 396：1745-1757, 2020

19）Perez-Ruiz F, et al：A two-stage approach to the treatment of hyperuricemia in gout；The “dirty dish” hypothesis. Arthritis Rheum 63：4002-4006, 2011